ZYME vs OCUL

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

ZYME

35.2
AI Score
VS
OCUL Wins

OCUL

61.5
AI Score

Investment Advisor Scores

ZYME

35score
Recommendation
SELL

OCUL

62score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZYME OCUL Winner
Revenue 7.00M 24.26M OCUL
Net Income -89.18M -167.38M ZYME
Net Margin -1274.4% -689.9% OCUL
Operating Income -89.30M -175.45M ZYME
ROE -111.0% -32.2% OCUL
ROA -22.5% -24.9% ZYME
Total Assets 396.96M 671.32M OCUL
Cash 179.41M 598.64M OCUL
Current Ratio 6.32 13.11 OCUL
Free Cash Flow -77.88M -141.29M ZYME

Relative Price Performance (Last 90 Days)

ZYME 1M: +3.4% · 3M: +24.4% OCUL 1M: -33.9% · 3M: -22.3%

Current Technical Phase

ZYME

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 61

RSI (14): 61.0 · Price: $28.44

OCUL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.1%), weak momentum, RSI 33

RSI (14): 33.4 · Price: $6.61

Fundamentals Snapshot

Metric ZYME OCUL
Market Cap — —
Forward P/E 31.5 -4.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.9% 0.0%
Gross Margin -2.5% -3.4%
Operating Margin -9.2% -6.1%
EPS -2.02 -1.40
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, OCUL is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.